Geron Corporation (GERN)

4.19 +0.11 (+2.696%)

IEX Real-Time Price

April 25, 2018 EST.

Nasdaq Global Select : Healthcare

Prev Close 4.08

Price Open 4.15

Volume: 4.19M

Avg Volume: 12.2M

Market Cap: 673.14M

P/E Ratio -23.28

52 Wk Range 1.74-6.68



GERN Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-03-29
155.65M
44.09M
3.57
28.32%

2018-03-15
155.65M
37.03M
14.31
23.79%

2018-02-28
154.23M
35.51M
11.34
23.02%

2018-02-15
154.23M
35.38M
10.93
22.94%




GERN Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-05-08
Q1 2018
N/A
-0.04 (1)
0.00
0.00

2018-03-16
Q4 2017
AMC
-0.04 (2)
-0.05
-0.01

2018-03-07
Q4 2017
N/A
-0.04 (2)
-0.05
-0.01

2017-11-01
Q3 2017
AMC
-0.05 (2)
-0.05
-0.01

News

Don't Be Surprised When Johnson & Johnson Acquires Geron Within A Year (2018-04-25 12:18 SeekingAlpha)

The Rumor Mill Rumors of a buyout for Geron (NASDAQ: GERN ) have been around for a couple years now, but in the last several months the topic of a buyout has become a hot topic for many Geron investors. Last week I presented a logical argument why GERN is a great investment in terms of…

 

Lifshitz & Miller LLP Announces Investigation of Analogic Corp., Babcock & Wilcox Enterprises, Inc., Coastway Bancorp, Inc., Geron Corporation, ICICI Bank Ltd., Live Nation Entertainment, Inc., Lumentum Holdings Inc. and VeriFone Systems, Inc. (2018-04-24 12:39 PR Newswire)

NEW YORK , April 24, 2018 /PRNewswire/ -- Analogic Corp. (ALOG) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the proposed sale of Analogic to Altaris Capital Partners LLC, for $84.00 per share. If you ar…

 

The No BS Plan Report, Week 10: Where The Reliable Falter (2018-04-22 12:57 SeekingAlpha)

Author's note: As always, I'm happy to answer questions in the comments below, but you can get direct access to me in the Total Pharma Tracker chatroom if you want to discuss in further detail! Right now you can get a no-obligation free trial to the service for two weeks. Welcome to an…

 

Johnson & Johnson Reaffirms Geron's Imetelstat As Lead Oncology Pipeline Drug (2018-04-19 12:26 SeekingAlpha)

An extremely bumpy 2018 for Geron ( GERN ) shareholders is taking a sharp turn for the better as Johnson & Johnson ( JNJ ) reconfirms Tuesday that Geron's Imetelstat remains their lead oncology pipeline opportunity. JNJ has exclusive development rights for the drug and is currently running…

 

The Logical Argument For Geron (2018-04-17 11:32 SeekingAlpha)

Editor's note: Seeking Alpha is proud to welcome Invest With Logic as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more "A W…

 


Statistics

Shares Outstanding: 160.65M

Top 15 Institution Percent: 36.80

Price To Sales: 1241.42

Price To Book: 6.31

Revenue: 874000

Gross Profit: N/A

Cash: 291.03M

Debt: N/A

Return On Assets: -21.57

Return On Equity: -22.94

Profit Margin: N/A

Price History

Beta: 2.30

50-day Moving Avg: 3.43

200-day Moving Avg: 2.48

YTD Change: 131.49

5-day Change: 13.55

1-month Change: -29.93

3-month Change: 107.43

6-month Change: 105.39

1-year Change: 63.04

Revenue Per Share: 0.00

Revenue Per Employee: 48556.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Geron Corporation

Exchange: Nasdaq Global Select

Industry: Biotechnology

Sector: Healthcare

Website: http://www.geron.com

Geron Corp is a biopharmaceutical company. It supports the clinical stage development of a telomerase inhibitor, imetelstat.